Retatrutide

Also known as: LY3437943, Triple G, GGG Agonist

A first-in-class triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously — producing the most dramatic weight loss results ever seen in clinical trials (up to 24% at 48 weeks).